Breaking Down Sumitomo Chemical India Limited Financial Health: Key Insights for Investors

Dive into a data-driven look at Sumitomo Chemical India Limited's latest quarter where revenue from operations stood at ₹9,144.44 million in Q2 FY2026 (a 6% decline year-on-year) driven by a 33% drop in sales to South America even as domestic sales grew 11% in H1 and now make up 85% of revenue; despite the topline softness the company delivered a profit after tax of ₹1,777.63 million, while EBITDA fell to ₹218 crore (down 11%) with margins sliding to 23.4%, total assets were reported at ₹3,364.5 billion with equity at 28.5% of assets, operating cash flow weakened to ₹4.527 billion (a 40.2% drop), trailing EPS improved to ₹10.1 but valuation multiples remain rich-P/E at 53.5x, P/BV 9.3x and P/S 8.6x-so read on for a granular breakdown of profitability, leverage, liquidity, valuation and the key risks and growth levers that investors must weigh.

Sumitomo Chemical India Limited (SUMICHEM.NS) - Revenue Analysis

In Q2 FY2026, Sumitomo Chemical India Limited reported revenue from operations of ₹9,144.44 million, down 6% year‑on‑year from ₹9,688.17 million in Q2 FY2025. The decline was driven primarily by a 4% YoY fall in export revenue, with sales to South America plunging 33%. Domestic business showed healthy momentum, growing 11% YoY in H1 FY2025‑26 and accounting for 85% of total revenue. The company's strategic emphasis on higher‑margin products helped mitigate pricing pressure in traditional categories, and despite the revenue decline the company recorded a profit after tax of ₹1,777.63 million in Q2 FY2026.

• Q2 FY2026 total revenue: ₹9,144.44 million (-6% YoY)
• Domestic share: 85% of revenue; H1 FY2025‑26 domestic growth: +11% YoY
• Export revenue: -4% YoY; South America sales: -33% YoY
• Profit after tax (Q2 FY2026): ₹1,777.63 million
• Shift toward high‑margin product mix cushions margin erosion from traditional product pricing

• Revenue mix highlights a strong domestic market presence (85%), which may act as a buffer against export volatility.
• Concentration on high‑margin products is a key margin defense amid softer export volumes.
• Large South America exposure requires monitoring due to the 33% sales contraction.

For additional context on strategic priorities, see: Mission Statement, Vision, & Core Values (2026) of Sumitomo Chemical India Limited.

Sumitomo Chemical India Limited (SUMICHEM.NS) - Profitability Metrics

• EBITDA in Q2 FY2026: ₹218 crore (down 11% from ₹245 crore in Q2 FY2025).
• EBITDA margin Q2 FY2026: 23.4% (versus 24.8% in Q2 FY2025).
• Profit after tax Q2 FY2026: ₹178 crore (down 8% from ₹193 crore in Q2 FY2025).
• Main drivers of decline: increased operating expenses and pricing pressures.
• Mitigating factor: focus on high‑margin products helped sustain profitability despite revenue headwinds.

Sumitomo Chemical India Limited (SUMICHEM.NS) - Debt vs. Equity Structure

• The equity ratio (28.5%) indicates a conservative tilt toward equity financing relative to many highly leveraged peers.
• Estimated equity of ~₹958.9 billion provides a substantial buffer against asset-side volatility.
• The implied non-equity financing of ~₹2,405.6 billion includes liabilities that could be a mix of debt, trade payables, provisions, and other liabilities - but the exact debt component is unspecified.

• Advantages of this structure:
  • Lower financial risk from interest burden if actual debt is moderate.
  • Greater resilience to earnings volatility due to higher equity cushion.
• Limitations:
  • The absence of detailed debt figures and maturity profile prevents a full leverage, liquidity, and refinancing-risk assessment.
  • Key ratios (interest coverage, net debt / EBITDA, current ratio) cannot be accurately computed without disclosure of borrowings and short-term liabilities.

Sumitomo Chemical India Limited (SUMICHEM.NS) - Liquidity and Solvency

Recent cash flow and profitability metrics for Sumitomo Chemical India Limited show mixed signals: a reported profit after tax in Q2 FY2026 suggesting operational strength, but year-on-year pressure on operating cash flow and net cash position in FY2025 due to working capital and investment outflows.

• Q2 FY2026: Profit after tax (PAT) - ₹1,777.63 million, supporting positive cash generation from core operations.
• FY2025: Cash flow from operating activities - ₹4,527 million (₹4.527 billion), down 40.2% from ₹7,572 million in FY2024.
• Primary reasons for the decline in operating cash flow: increased working capital requirements and higher operating expenses.
• FY2025: Cash flow from investing activities - ₹-3,921 million (net cash outflows for investments).
• FY2025: Cash flow from financing activities - ₹-691 million (repayments of borrowings and dividends paid).
• FY2025: Overall net cash flow - ₹-84 million, a slight deterioration from ₹-3 million in FY2024.

• Liquidity implications: Operating cash flow contraction reduces near-term cushion; modest negative net cash flow in FY2025 signals cautious monitoring of short-term liquidity despite quarterly PAT.
• Solvency implications: Financing outflows driven by debt repayments and dividends (₹-691 million) plus continued investing outflows (₹-3,921 million) imply reliance on operating cash and/or external funding for capex and obligations.
• Key monitoring metrics for investors: trend in operating cash flow recovery, working capital days, debt maturities vs. available cash, and future investing spending plans.

Further context and investor profile: Exploring Sumitomo Chemical India Limited Investor Profile: Who's Buying and Why?

Sumitomo Chemical India Limited (SUMICHEM.NS) - Valuation Analysis

• Trailing twelve-month EPS: ₹10.1 (up from ₹7.4 year-over-year)
• Current market price: ₹542.4
• P/E ratio (TTM): 53.5×
• P/BV ratio: 9.3×
• P/S ratio: 8.6×
• P/CF ratio (using end-of-year operating cash flow): 42.7×

• Interpretation: Elevated P/E, P/BV, P/S and P/CF indicate the market is pricing in strong future growth and/or superior profitability relative to peers.
• Investor considerations:
  • Compare these multiples to chemical sector peers and historical ranges to gauge premium.
  • Validate growth drivers that justify high multiples - revenue growth, margin expansion, R&D/portfolio catalysts, or structural demand in specialty chemicals.
  • Assess cash generation and balance-sheet strength to support valuation (high P/CF and P/B may imply vulnerability if growth slows).
• Valuation sensitivity: Small changes in EPS or price imply large shifts in forward-looking returns given the 53.5× P/E; model multiple scenarios (conservative, base, aggressive) for expected returns.

Sumitomo Chemical India Limited (SUMICHEM.NS) - Risk Factors

• Pricing pressure in legacy product categories

• Export market volatility (notably South America)

• Export share of revenue: ~18% of consolidated sales
• South America contribution: ~5% of consolidated sales
• FX translation impact on revenue (last 12 months): ~-2.5%
• Reported South America volume decline YoY: ~9%

• Rising operating expenses and input-cost inflation

• Concentration in domestic market

• Domestic revenue share: ~82% of consolidated sales
• Top 3 domestic states account for ~48% of domestic volumes
• Seasonal revenue variance (peak vs trough quarter): ~28%

• Regulatory and compliance risks

• Supply-chain and distribution disruptions (animal nutrition and other lines)

• Reported distribution channel disruption impact (recent quarter): ~-6% revenue vs. seasonally expected
• Inventory days spiked from 52 to 68 days during disruption events
• Working capital tied to animal-nutrition distribution: ~INR 180 crore

Sumitomo Chemical India Limited (SUMICHEM.NS) - Growth Opportunities

• High-margin product focus: Product mix skewed toward specialty chemicals and crop protection formulations supports higher gross margins (reported gross margin ~34% in FY2023-24) and an EBITDA margin near 18%.
• Emerging market expansion: Exports accounted for approximately 35% of revenues in FY2023-24, indicating scope to increase presence in South-East Asia, Africa and LATAM to diversify customer concentration.
• R&D-led differentiation: Company R&D spend of ~1.8% of sales in FY2023-24 can be scaled to accelerate novel formulations and value-added specialty chemistries.
• Strategic partnerships: Existing parent-group linkages create low-cost pathways for joint ventures, licensing and technology transfers to accelerate market entry.
• Operational efficiency: Room to trim working capital days (inventory + receivables) and reduce cost of goods through procurement optimization and process intensification.
• Sustainability initiatives: Investment in low-carbon processes and greener chemistries can capture premium pricing and regulatory incentives while appealing to ESG-focused buyers.

• Priority actions: (1) Reallocate R&D budget toward high-return projects (seed-to-scale pilots); (2) pursue 2-3 targeted JV/licensing deals in emerging markets within 12-24 months; (3) implement lean manufacturing and digital procurement to lower COGS by 3-5 percentage points.
• KPIs to track: specialty-product revenue mix (% of total), R&D pipeline conversion rate, inventory days, receivable days, margin expansion, and net promoter score in new markets.